Skip to main content

22-06-2020 | COVID-19 | News

News in brief

COVID-19 hospitalization, mortality rates in RMD patients may not differ from general population

Author: Claire Barnard


medwireNews: Preliminary findings from the Spanish BIOBADASER registry suggest that patients with rheumatic and musculoskeletal diseases (RMDs) may not have an elevated risk for COVID-19 hospitalization or mortality compared with the general population.

Jose Alvaro-Gracia (Hospital General Universitario Gregorio Marañón, Madrid) and colleagues report that among 41 patients with RMDs treated with biologic (b) or targeted synthetic (ts)DMARDs who received a COVID-19 diagnosis, 68.3% required hospital admission, 14.6% were admitted to the intensive care unit, and 7.3% died. By comparison, the COVID-19 hospitalization and mortality rates for the Spanish general population are 53.6% and 12.0%, respectively, they say.

The most commonly represented RMD in the BIOBADASER population was rheumatoid arthritis (51.2%), followed by spondyloarthritis (29.3%); 61.0% of patients were female and the average age was 59.4 years. Tumor necrosis factor inhibitors were the most frequently used type of DMARD (43.9%), followed by Janus kinase inhibitors (17.1%), interleukin (IL)-6 inhibitors (12.2%), and IL-17A inhibitors (12.2%). The majority of patients (83.3%) were also taking glucocorticoids, and 41.5% were on methotrexate.

Writing in a correspondence to the Annals of the Rheumatic Diseases, Alvaro-Gracia and team acknowledge that the small number of patients in their study “limits the possibility of drawing solid conclusions.” Nonetheless, they say their results “point in the direction that COVID-19 course and mortality in patients with RMDs treated with b/tsDMARD do not differ from the general population.”

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

22 June 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Ann Rheum Dis 2020; 79: 988–99


New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?